JPRN-UMIN000045530尚未招募未知
Observational Study of BRAF Inhibitor Combination Therapy for BRAF mutant Metastatic Colorectal Cancer including Biomarker Research: BEETS trial(JACCRO CC-18) - BEETS trial(JACCRO CC-18)
JACCRO0 个研究点目标入组 200 人开始时间: 2021年9月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients with interstitial pneumonia or pulmonary fibrosis (2) Patients with a history of acute myocardial infarction or acute coronary syndrome (unstable angina, coronary artery bypass surgery, coronary angioplasty, stenting, etc.) within 6 months prior to enrollment (3) Patients with a history or current evidence of clinically significant congestive heart failure or cardiac arrhythmia within 6 months prior to enrollment (4) Patients with a history of clinically significant thromboembolic or cerebrovascular events within 6 months prior to enrollment (5) Patients with a history of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive drugs or surgery) within 12 months prior to enrollment (6) Patients with active multiple cancers (7) Patients with active infectious diseases that require systemic treatment (8) Patients with positive HBs antigen, HCV antibody, or HIV antibody (9) Patients judged by the principal investigator or sub-investigator to be inappropriate for the safe conduct of this study
研究者
相似试验
已完成
2 期
BRF113928: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer10029107non-small cell lung cancerlung cancerNL-OMON47910ovartis20
已完成
1 期
EVICT: The erlotinib and vemurafenib in combination trial.A Phase I/II Trial of the combination of BRAF and EGFR inhibition in BRAF V600E mutant colorectal, advanced or metastatic lung adenocarcinoma and other cancers.Colorectal Cancer (metastatic)Lung Cancer (metastatic)Cancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - Lung - Non small cellACTRN12614000486628Peter MacCallum Cancer Centre46
已完成
不适用
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic MelanomaMalignant MelanomaNCT02143999Hoffmann-La Roche403
进行中（未招募）
1 期
A study to test a new drug for treating non-small cell lung cancerAdvanced non-small cell lung cancer and BRAF mutationsMedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001161-41-ITGlaxoSmithKline Research and Development Limited100
进行中（未招募）
1 期
A study to test a new drug for treating non-small cell lung cancerEUCTR2011-001161-41-GBovartis Pharma Services AG166